



## FEATURED OPTIONS RADAR REPORT



### CureVac Bulls Position for Another COVID Vaccine Winner

**Ticker/Price:** CVAC (\$104)

#### Analysis:

**CureVac (CVAC)** large trade on 4/15 sold 3000 May \$85 puts to buy 3000 of the \$120/\$135 call spreads at a net credit, so more of a spread willing to own shares below \$85 but positioned for upside. CVAC has seen some bullish action previously with 1000 May \$75 puts sold to buy the \$100/\$120 call spreads and January 2023 has some size bullish positions in long deep ITM calls and short puts. CVAC was a top chart set-up into this week forming a large triangle on the weekly and shares with a big weekly base breakout after basing at support with weekly RSI moving back above 50 and out of a downtrend. The pattern sets up for a potential move to new highs. CVAC is a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. The current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology and protein therapy. CVAC currently has a \$20B market cap with no major revenues, a clinical-stage biotech. CVAC has an ample EUR 1.32B cash position. The CVAC trade came as the company held its earnings call and provided a business update. Its COVID-19 vaccine candidate CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission. It also has pivotal Phase 2b/3 in Europe and Latin America fully recruited with over 40,000 participants. Interim analysis for vaccine efficacy expected in Q2 2021. CVnCoV demonstrates, in preclinical challenge study, full protection from infections with Variant of Concern B.1.351 (South Africa variant). CVAC is expected to manufacture up to 300 million doses of CVnCoV by end of 2021 and up to one billion doses in 2022. It has partnerships with Bayer, GlaxoSmithKline, and the UK government. There was an interesting report recently that CVAC and Tesla are working on creating a drug printer for vaccines and customized drugs. Analysts have an average target of \$84 and short interest low at 2.6% of the float.

#### Hawk Vision:



**Hawk's Perspective:** CVAC may emerge as a real winner in the European COVID battle and all signs looking positive into key data.

**Confidence Ranking:** \$\$